5-Cyano-6-isopropoxy-4-methylsulfanyl-pyridine-2-carboxylic acid 4-methanesulfonyl-benzylamide | 926308-32-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-Cyano-6-isopropoxy-4-methylsulfanyl-pyridine-2-carboxylic acid 4-methanesulfonyl-benzylamide
• CAS: 926308-32-9
• 化学式: C₁₉H₂₁N₃O₄S₂
• 分子量: 419.525
• InChiKey: UYZYYKFPGBCXBH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  28.0
• 可旋转键数：
  7.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  109.15
• 氢给体数：
  1.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  5-Cyano-6-isopropoxy-4-methylsulfanyl-pyridine-2-carboxylic acid 4-methanesulfonyl-benzylamide 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Hemodynamic effects of potent and selective JNK inhibitors in anesthetized rats: Implication for targeting protein kinases in metabolic diseases

  摘要：

  The hemodynamic effects of a series of potent and selective 4-aminopyridine carboxamide-based pan-JNK inhibitors were assessed in an anesthetized rat model. The effects of these agents on mean arterial pressure, heart rate, cardiac contractility, and peripheral vascular resistance are described, and the implication for targeting protein kinases in metabolic diseases is discussed. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.10.013
• 作为产物：
  描述：

  6-Dimethoxymethyl-2-isopropoxy-4-methylsulfanyl-nicotinonitrile 在 盐酸 、 氢氧化钾 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 silver nitrate 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.5h， 生成 5-Cyano-6-isopropoxy-4-methylsulfanyl-pyridine-2-carboxylic acid 4-methanesulfonyl-benzylamide
  参考文献：
  名称：

  Hemodynamic effects of potent and selective JNK inhibitors in anesthetized rats: Implication for targeting protein kinases in metabolic diseases

  摘要：

  The hemodynamic effects of a series of potent and selective 4-aminopyridine carboxamide-based pan-JNK inhibitors were assessed in an anesthetized rat model. The effects of these agents on mean arterial pressure, heart rate, cardiac contractility, and peripheral vascular resistance are described, and the implication for targeting protein kinases in metabolic diseases is discussed. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.10.013